Screener
Haemonetics HAE Total Liabilities & Equity
Total Liabilities & Equity at other companies
Other financials
Where this comes from
Reported directly by Haemonetics in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.
The source filing: Haemonetics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 6:09 AM EDT
- Fiscal quarter
- Q1 FY2027
- Calendar quarter
- Q2 2026
- Accession
- 0000313143-26-000120
| Line item | June 27, 2026 | March 28, 2026 |
|---|---|---|
| Other long-term liabilities | 57,171 | 59,393 |
| Stockholders’ equity: | ||
| Common stock, $0.01 par value; Authorized — 150,000,000 shares; Issued and outstanding — 45,471,313 shares as of June 27, 2026 and 45,252,667 shares as of March 28, 2026 | 455 | 453 |
| Additional paid-in capital | 566,759 | 554,137 |
| Retained earnings | 311,516 | 279,344 |
| Accumulated other comprehensive loss | (41,629) | (37,614) |
| Total stockholders’ equity | 837,101 | 796,320 |
| Total liabilities and stockholders’ equity | $2,365,400 | $2,395,925 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Haemonetics's total liabilities & equity?
- Haemonetics (HAE) reported total liabilities & equity of $2.37B in Q2 2026.
- How has Haemonetics's total liabilities & equity changed year-over-year?
- Haemonetics's total liabilities & equity decreased by 3.9% year-over-year, from $2.46B to $2.37B.
- What is the long-term trend for Haemonetics's total liabilities & equity?
- Over 5 years (2021 to 2026), Haemonetics's total liabilities & equity has grown at a 5.7% compound annual growth rate (CAGR), from $1.82B to $2.4B.
- What does total liabilities & equity mean?
- Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.
Ask your AI about Haemonetics's total liabilities & equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude